Has Type 1 or Type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%
Has a decrease in vision in the study eye determined by the Investigator to be primarily the result of diabetic macular edema (DME)
For participants who are treatment-naïve for DME, the diagnosis must have been made within 9 months of screening. For all treatment-experienced participants, the first treatment should have been no longer than 3 years prior to the Screening visit
You may not be if
Has had renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis or has renal failure anticipated to require hemodialysis or peritoneal dialysis at any time during the study
Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days to first dose of study intervention
Has newly diagnosed or previously untreated diabetes mellitus and initiated oral or injectable anti-diabetic medication within 3 months to first dose of study intervention
Has history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening
Has any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy in the study eye within 90 days of screening
Has advanced or uncontrolled glaucoma in the study eye
Has any history of retinal detachment or treatment or surgery for retinal detachment in the study eye
Has active retinal disease other than the condition under investigation in the study eye
Has uncontrolled blood pressure at screening
Clareo Health | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
